Abstract
Purpose of Review
This review aims to give a brief update how to do RECIST 1.1, irRECIST 1.1, and mRECIST.
Recent Findings
The revised Response Evaluation Criteria in Solid Tumors (RECIST 1.1) are currently representing the most commonly used and validated response criteria for objective treatment monitoring of conventional chemotherapies in solid tumors. However, with the introduction of novel molecular drugs and local tumor therapies, such as selective transarterial chemoembolization (TACE) at hepatocellular carcinomas (HCC), limitations of the conventional RECIST 1.1 became obvious due to specific response pattern, which are not reflected. Thus, for a comprehensive evaluation of immunotherapeutic agents new immune-related RECIST (irRECIST 1.1) and of selective HCC treatment modified RECIST (mRECIST) criteria have been published.
Summary
RECIST 1.1 presents the most used response criteria for conventional chemotherapies in solid tumors. For specific evaluation of immunotherapeutic agents irRECIST 1.1 and of selective HCC treatment mRECIST have been established.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
WHO. WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48, Geneva; 1979.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16. doi:10.1093/jnci/92.3.205.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. doi:10.1016/j.ejca.2008.10.026.
Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45:261–7. doi:10.1016/j.ejca.2008.10.028.
• Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2:17. doi:10.1186/2051-1426-2-17. Original publication of irRECIST 1.1.
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-1247132. Original publication of mRECIST for HCC.
Hodi FS, O’Day S, McDermott DF, Weber RW, Sosman J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:2255–65. doi:10.1056/NEJMoa1207290.
Spiro J, Maintz D, Persigehl T. Responsekriterien bei malignem Melanom—RECIST und irRC. Radiologe. 2015;2:127–35. doi:10.1007/s00117-014-2763-y.
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. doi:10.1158/1078-0432.CCR-09-1624.
Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:3936–43. doi:10.1158/1078-0432.CCR-13-0895.
Kim MN, Kim BK, Han K-H, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol. 2015;9:335–48. doi:10.1586/17474124.2015.959929.
Hyun D, Shin SW, Cho SK, Park KB, Park HS, et al. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol. 2015;56:1437–45. doi:10.1177/0284185114560937.
Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118:16–22. doi:10.3109/03009734.2012.729104.
Shim JH, Lee HC, Kim S-O, Shin YM, Kim KM, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708–18. doi:10.1148/radiol.11110282.
Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118:147–56. doi:10.1002/cncr.26255.
ACR. American College of Radiology - Liver Imaging Reporting and Data System version 2014. 2014. https://nrdr.acr.org/lirads/.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Oncology.
Rights and permissions
About this article
Cite this article
Henze, J., Maintz, D. & Persigehl, T. RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do. Curr Radiol Rep 4, 48 (2016). https://doi.org/10.1007/s40134-016-0178-4
Published:
DOI: https://doi.org/10.1007/s40134-016-0178-4